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Abstract
Background: Existing data are not consistently supportive of improved clinical outcome when vancomycin dosing
regimens aimed at achieving target trough levels are used. A retrospective, post hoc, subgroup analysis of
prospectively collected data from the Phase 3 ATTAIN trials of telavancin versus vancomycin for treatment of
nosocomial pneumonia was conducted to further investigate the relationship between vancomycin serum trough
levels and patient outcome.
Methods: Study patients were enrolled in 274 study sites across 38 countries. A total of 98 patients had
Staphylococcus aureus nosocomial pneumonia and vancomycin serum trough levels available. These patients were
grouped according to their median vancomycin trough level; < 10 μg/mL, 10 μg/mL to < 15 μg/mL, and≥ 15 μg/mL.
Results: Clinical cure rates in the < 10 μg/mL, 10 μg/mL to < 15 μg/mL, and≥ 15 μg/mL vancomycin trough level
groups were 70% (21/30), 55% (18/33), and 49% (17/35), respectively (p = 0.09), and the frequencies of patient death
were 10% (3/30), 15% (5/33), and 20% (7/35), respectively (p = 0.31). Renal adverse events were more frequent in
the≥ 15 μg/mL (17% [6/35]) than the < 10 μg/mL (0%) and 10 μg/mL to < 15 μg/mL (3% [1/33]) trough level groups
(p < 0.01). When patients with acute renal failure or vancomycin exposure within 7 days prior to study medication were
excluded, clinical cure rates in the < 10 μg/mL, 10 μg/mL to < 15 μg/mL, and≥ 15 μg/mL vancomycin trough level
groups (71% [12/17], 60% [9/15], and 27% [3/11], respectively; p = 0.04) and the number of deaths (12% [2/17], 20%
[3/15], and 45% [5/11], respectively; p = 0.07) demonstrated a trend towards worse outcomes in the higher vancomycin
trough level groups.
Conclusions: The findings of our study suggest that higher vancomycin trough levels do not result in improved
clinical response but likely increase the incidence of nephrotoxicity.
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Background
Staphylococcus aureus has emerged as a major cause of
nosocomial pneumonia (NP), with rates of methicillin-
resistant strains (MRSA) as high as 70% reported in some
US studies [1]. Vancomycin, linezolid, and telavancin are
currently approved for treatment of NP due to MRSA in
the United States [2].
Vancomycin serum trough levels of 5–15 μg/mL have
previously been targeted to optimize clinical outcome in
patients with NP, although more recent literature suggests
a vancomycin trough level of 15–20 μg/mL [3]. This range
of trough concentrations is required to achieve the pre-
sumed optimal vancomycin AUC/MIC (area under the
curve/minimum inhibitory concentration) target of > 400
for S. aureus with MIC values ≤ 1 μg/mL [3].
Existing data are not consistently supportive of im-
proved clinical outcome when vancomycin dosing regi-
mens aimed at achieving this AUC/MIC target are used
[4,5]. Most recently, the results of the Phase 4 ZEPHyR
trial comparing vancomycin with linezolid for MRSA
NP found that higher trough levels of vancomycin were
associated with lower cure rates [6].
In terms of safety, several investigations indicate
that vancomycin serum levels > 15 μg/mL [5,7], and
particularly > 20 μg/mL [8], can result in significant
nephrotoxicity. Using Monte Carlo simulation and a
pharmacokinetic/pharmacodynamic model derived from
patient data, Patel et al. [9] suggested that for infections
due to S. aureus with MIC values ≥ 1 μg/mL, vanco-
mycin doses with an acceptable probability of AUC/
MIC target attainment would result in unacceptable
levels of nephrotoxicity.
Using prospectively collected data from the Assess-
ment of Telavancin for Treatment of Hospital-Acquired
Pneumonia (ATTAIN) Phase 3 clinical trials, we sought
to further elucidate the relationship between measured
vancomycin trough concentrations and clinical response,
overall safety, incidence of nephrotoxicity, and mortality
in patients with S. aureus NP.
Methods
The ATTAIN trials were two identical, randomized,
double-blind, comparator-controlled, parallel-group, Phase
3 studies (NCT00107952 and NCT00124020) investigating
the efficacy and safety of telavancin versus vancomycin for
treatment of Gram-positive NP in adult patients [10]. The
institutional review board at each site approved the
protocol (see Additional files 1 and 2), and all patients
or their authorized representatives provided written in-
formed consent.
Vancomycin was administered at 1 g every 12 hours
for 7–21 days. Investigators were not provided with spe-
cific vancomycin trough recommendations as there were
no authoritative guidelines available when the studies
were conducted. Vancomycin dosing could be monitored
and adjusted for weight and/or renal function according
to site-specific standard procedures (while maintaining
study blind).
The analysis population for the current investigation
consisted of patients in the ATTAIN all-treated (AT)
population (all randomized patients who received ≥ 1 dose
of study medication) who had S. aureus NP and vanco-
mycin serum trough levels available. These patients were
grouped according to their median vancomycin trough level
over the study period; < 10 μg/mL, 10 μg/mL to < 15 μg/
mL, and ≥ 15 μg/mL.
Clinical cure was defined as improvement or lack of
progression of baseline radiographic findings at end of
study therapy (EOT) and resolution of signs and symp-
toms of pneumonia at the test of cure (TOC) visit. Failure
was defined as persistence or progression of signs and
symptoms or progression of radiological signs of pneumo-
nia at EOT; termination of study medications due to “lack
of efficacy” and initiation within two calendar days of a
different potentially effective anti-staphylococcal medica-
tion; death on or after Day 3 attributable to primary infec-
tion; or relapsed infection at TOC. Renal adverse events
(AEs) were defined by the investigators as acute renal fail-
ure, chronic renal failure, renal impairment, renal insuffi-
ciency, and/or by laboratory values as increased creatinine
(at least 1.5× baseline to a value ≥ 1.5 mg/dL). In patients
with preexisting renal dysfunction, renal adverse events
were defined if they had a worsening of their baseline
renal function during the study. Increased creatinine was
defined programmatically using laboratory data. Kruskall-
Wallis for continuous variables (e.g., age and Acute Physi-
ology and Chronic Health Evaluation II (APACHE II)
score) and Cochran-Mantel-Haenszel general association
statistics for categorical variables (e.g., acute renal failure
and bacteremia) were used to compare the baseline
characteristics across the three vancomycin trough groups
(< 10 μg/mL, 10 μg/mL to < 15 μg/mL, and ≥ 15 μg/mL).
Cochran-Armitage trend test was used to evaluate clinical
outcomes. No adjustment for multiple comparisons was
made and a nominal two-sided p-value of < 0.05 was con-
sidered statistically significant.
Results
Vancomycin serum trough levels were available from 98
patients with S. aureus NP in the ATTAIN AT population;
30, 33, and 35 patients had median vancomycin trough
levels of < 10 μg/mL, 10 μg/mL to < 15 μg/mL, and ≥ 15 μg/
mL, respectively. Baseline patient characteristics were gen-
erally similar between the three vancomycin trough level
groups, although there was a greater proportion of patients
who had failed prior antibiotic treatment in the higher
vancomycin trough groups (p = 0.002; Table 1). While not
statistically significantly different, more patients in the
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higher vancomycin trough groups had preexisting acute
renal failure or multilobar pneumonia, and there were more
bacteremic patients in the lower vancomycin trough groups
(Table 1). Despite these differences, APACHE II scores
were similar between the vancomycin trough groups
(Table 1). Median trough levels were similar in patients
who received ≤ 7 days or > 7 days of therapy with vanco-
mycin (data not shown).
No statistically significant relationship was observed be-
tween clinical cure or the number of deaths and vanco-
mycin trough level (Table 2). In addition, median length
of therapy did not differ between the groups (Table 2).
However, when patients with acute renal failure or vanco-
mycin exposure within the 7 days prior to the first dose
of study medication were excluded, there was a trend to-
wards lower clinical cure rates (p = 0.04) and a greater
number of deaths (p = 0.07) in the higher vancomycin
trough groups (Table 2). There was a greater incidence of
serious AEs and renal AEs as the vancomycin trough level
increased (p = 0.03 and p < 0.01, respectively) (Table 2).
This relationship was maintained when patients with acute
renal failure or vancomycin exposure within the 7 days
prior to the first dose of study medication were excluded
(p = 0.02 and p = 0.01, respectively) (Table 2).
Discussion
This analysis of patients treated with vancomycin for NP
suggests that clinical outcomes were not improved when
recommended vancomycin trough levels (≥ 15 μg/mL)
were achieved [3]. Importantly, all but one patient was
infected with S. aureus isolates with MIC values ≤ 1 μg/
mL, indicating that nearly all patients with a vancomycin
trough level ≥ 15 μg/mL should have achieved the rec-
ommended AUC/MIC target [3]. The worse outcomes
observed in the higher vancomycin trough groups may
reflect differences in patient baseline characteristics be-
tween the groups. Specifically, acute renal failure was
more common in the higher vancomycin trough groups,
which may have influenced vancomycin distribution, and
is also associated with poor clinical outcomes. Further-
more, investigators may have employed more aggressive
dosing in patients with infections that were perceived to
be more severe due to prior antimicrobial treatment fail-
ure or multilobar involvement, both of which were more
common in the higher vancomycin trough groups.
There was more nephrotoxicity associated with the
higher vancomycin troughs, consistent with previous re-
ports [5,7,8,11] and a recent prospective study [12]. Al-
though this may also be attributable to a greater number
Table 1 Baseline characteristics and clinical outcomes of ATTAIN study patients with Staphylococcus aureus nosocomial
pneumonia according to vancomycin trough levels
Vancomycin trough level (μg/mL), n (%)* p†
< 10 (n = 30) 10 to < 15 (n = 33) ≥ 15 (n = 35)
Age (mean ± SD, year) 60 ± 20 69 ± 13 69 ± 14 0.14
APACHE II score (mean ± SD) 16 ± 5 17 ± 7 18 ± 6 0.45
Creatinine clearance ≤ 50 mL/min 10 (33) 18 (55) 14 (40) 0.22
Acute renal failure 2 (7) 5 (15) 10 (29) 0.06
Multilobar pneumonia 17 (57) 19 (58) 28 (80) 0.08
Bacteremia‡ 6 (20) 2 (6) 2 (6) 0.10
Resident in ICU 20 (67) 24 (73) 28 (80) 0.48
Use of vasopressor/inotropic 5 (17) 5 (15) 7 (20) 0.87
Shock 2 (7) 2 (6) 4 (11) 0.68
Potentially nephrotoxic prior antibiotic therapy
Vancomycin 11 (37) 14 (42) 17 (49) 0.63
Amikacin 1 (3) 1 (3) 2 (6) –
Gentamicin 0 2 (6) 1 (3) –
Prior antibiotic failure 11 (37) 18 (55) 28 (80) 0.002
MRSA 20 (67) 26 (79) 30 (86) 0.18
Staphylococcus aureus MIC > 1 μg/mL 0 0 1 (3) 0.41
APACHE II, Acute Physiology and Chronic Health Evaluation II; ATTAIN, Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia; ICU, intensive
care unit; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; SD, standard deviation.
*Unless otherwise stated.
†Kruskall-Wallis or Cochran-Mantel-Haenszel general association.
‡S. aureus recovered from baseline blood cultures.
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of patients with severe infections in the higher trough
population, exclusion of the patients with major risk fac-
tors for nephrotoxicity did not change the observed trend.
Concomitant medications also may contribute to the renal
toxicity observed. In the study by Hidayat et al. [13],
nephrotoxicity was reported in 11 of 95 subjects. Ten of
these 11 subjects received concomitant nephrotoxic agents;
in contrast, only 17 of the 84 subjects (20%) with no renal
toxicity received nephrotoxic agents (interestingly, all 11
cases of renal toxicity occurred in the 63 subjects who had
vancomycin trough levels of 15–20 μg/mL). A post hoc
examination of our own data revealed prior and/or
concomitant use of one or more known nephrotoxic agents
in 40%, 42%, and 54% of patients in the < 10 μg/mL,
10 μg/mL to < 15 μg/mL, and ≥ 15 μg/mL vancomycin
trough groups, respectively (data not shown).
The main limitation of this study is that it was a post hoc,
exploratory analysis; the ATTAIN studies were not de-
signed to evaluate the impact of vancomycin trough levels,
and as such, patients were not randomized to achieve a spe-
cific trough target. In addition, the sample size may be too
small to draw a definitive conclusion. However, the data
were obtained from rigorously monitored, registrational,
Phase 3 trials that likely capture critical information in a
more systematic fashion than retrospective studies.
Conclusion
In summary, the findings of our study suggest that
higher vancomycin trough levels do not result in im-
proved clinical response but likely increase the incidence
of nephrotoxicity. Prospective controlled studies are re-
quired to further assess the validity of the current vanco-
mycin dosing recommendations.
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